The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
The study was conducted in patients with mild to moderate COVID-19
Subscribe To Our Newsletter & Stay Updated
